E
ENYO Pharma
Biotech & Life Sciences · Lyon, France · Founded 2014
Clinical stage biotech with an innovative approach inspired by viruses MoreLess
ENYO Pharma is a biotechnology startup based in Brussels, Belgium, focused on developing innovative therapies for viral infections and liver diseases. The company leverages its proprietary discovery engine to identify and develop new drug candidates. ENYO Pharma's primary areas of research include chronic hepatitis B, non-alcoholic steatohepatitis (NASH), and COVID-19, among other viral threats.
The company serves a diverse range of clients, including healthcare providers, pharmaceutical companies, and research institutions. ENYO Pharma operates in the biopharmaceutical market, which involves the development and commercialization of drugs derived from biological sources.
ENYO Pharma's business model revolves around the research and development (R&D) of novel therapeutics. The company advances its drug candidates through various stages of clinical trials, aiming to demonstrate their safety and efficacy. Once a drug candidate shows promise, ENYO Pharma can either partner with larger pharmaceutical companies for further development and commercialization or bring the product to market independently.
The company generates revenue through multiple streams. These include licensing agreements, where other companies pay for the rights to develop and market ENYO Pharma's drug candidates. Additionally, ENYO Pharma may receive milestone payments as its drug candidates progress through clinical trials and regulatory approvals. The company also benefits from funding and grants, such as those from the European Union, to support its research initiatives.
ENYO Pharma's executive team comprises experienced leaders from the pharmaceutical industry and scientific experts in biology and drug development. This combination of expertise is crucial for driving the company's innovative approach and advancing its pipeline of drug candidates.
Keywords: biotechnology, drug development, viral infections, liver diseases, hepatitis B, NASH, COVID-19, clinical trials, licensing agreements, pharmaceutical partnerships.
Company overview
ENYO Pharma company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2014
- Headquarters
- Lyon, France
- Employees
- 41
- Open positions
- None listed
- Dealroom signal
- 84.5
Valuation & funding
ENYO Pharma funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Jun 2025 | $6.6M | $220M | Vesalius Biocapital Partners | ↗ |
| SERIES COther financing | Jan 2024 | $43M | $220M | OrbiMed · InnoBio · Bpifrance · Morningside | ↗ |
| SERIES BOther financing | Jun 2018 | $44M | $176M | Sofinnova Partners · InnoBio · OrbiMed · Bpifrance | ↗ |
| GRANTOther financing | Jul 2016 | $2.7M | — | European Innovation Council | — |
| SERIES AOther financing | Jan 2016 | $24M | $97M | Sofinnova Partners | ↗ |
| SERIES AOther financing | Dec 2014 | Sofinnova Partners | — | ||
| SPINOUTOther financing | Apr 2014 | ENS Lyon · French National Centre for Scientific Research - CNRS · INSERM · CNRS Innovation | ↗ |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $0 | — | −$2.5M | — |
| 2025 | $0 | — | −$2.5M | — |
| 2024 | $0 | — | −$2.5M | — |
| 2023 | $0 | — | −$2.5M | — |
| 2022 | $0 | — | −$2.5M | — |
| 2021 | $0 | — | −$2.5M | — |
| 2020 | $0 | — | −$2.5M | — |
Growth signals
ENYO Pharma website traffic
Latest recorded traffic for ENYO Pharma is 4.1K monthly website visits, up 78.3% over the last three months. ENYO Pharma's team grew 10.8% over the past year.
Comparisons
ENYO Pharma compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
ENYO Pharma's talent
Source: Dealroom Talent Intelligence.
Investors
16 investors on ENYO Pharma's cap table
Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.
Global footprint
Where ENYO Pharma has talent and traffic
team presence
In the news
Latest news about ENYO Pharma
Recent press, funding announcements, and product moves mentioning ENYO Pharma — open to read from the original sources.
Market sentiment
What the market is saying about ENYO Pharma
An AI-synthesized read of the highest-engagement posts about ENYO Pharma on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ENYO Pharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.